BPC-157 + TB-500 + KPV blend

Last Updated: August 2026

This is the classic tissue-repair research stack: BPC-157 (a gastric pentadecapeptide studied for angiogenesis and growth-factor-mediated repair), TB-500 (the actin-binding thymosin β4 fragment studied for cell migration and repair), and KPV (Lys-Pro-Val, the C-terminal tripeptide of α-MSH, studied for its anti-inflammatory action). It is research-use-only, not an approved product. Adding cosmetic GHK-Cu to this trio makes the four-peptide KLOW blend; dropping KPV leaves the two-peptide Wolverine healing pair.

Why are these three combined?

The pairing logic is complementary mechanisms: BPC-157 and TB-500 approach tissue repair through different pathways (growth-factor/angiogenic signaling vs actin-driven cell migration), while KPV adds an anti-inflammatory angle by dampening pro-inflammatory signaling (NF-κB) — so the stack aims to support repair while modulating the inflammation that accompanies injury. This is a mechanistic rationale, not a proven combined outcome.

What's the evidence and status?

The individual components have varying (largely preclinical) research bases, but the combination has not been validated in controlled human trials; it is an experiential/research stack, and BPC-157 and TB-500 are prohibited in sport (WADA). See each component's profile for its own evidence. Always dose by the individual component amounts printed on your vial, never by a generic "blend dose" — and because composition varies by vendor, re-check them for every batch. Evidence level: Component-level, largely preclinical; blend not clinically validated.

What is the regulatory status of BPC-157 + TB-500 + KPV's components?

None of the three peptides is approved by the FDA — or any other regulator — for human use as of August 2026; all three are sold strictly as research-use-only material. In April 2026 the FDA removed BPC-157, TB-500 and KPV from its 503A Category 2 bulk-substances list because the nominations had been withdrawn by the nominators — an administrative removal that did not add them to Category 1 or authorise pharmacy compounding. At its July 23–24, 2026 meeting the FDA's Pharmacy Compounding Advisory Committee voted to recommend BPC-157, TB-500 and KPV (each 8–6–1) for the 503A compounding list — advisory recommendations the FDA's own reviewers had opposed, which the agency has not finalized; formal rulemaking is not expected before 2027. In sport, BPC-157 is prohibited by WADA under S0 and TB-500/thymosin β4 under S2.3 (Growth Factors); KPV is not named on the WADA Prohibited List. Evidence level: regulatory status only — none FDA-approved; all three components largely preclinical (BPC-157 zero RCTs, TB-500 no human trial of the fragment, KPV no human trials); the blend has no controlled human trial.

How does Peptigrity verify a three-part blend?

Confirm each labeled component is present, correctly identified, and adequately pure via HPLC and mass-spec. Peptigrity collects independent third-party Certificates of Analysis for the BPC-157, TB-500 and KPV components from shops' official channels and verifies each for authenticity before publishing; because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly, and a community-funded Testing Grant to purchase and test vials anonymously is in development. The trust score weights lab purity and reviews equally (50/50). Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. See the COA red-flags guide.

Educational information only; not medical advice. This is a research-use-only stack, not an approved therapy. Consult a qualified healthcare provider. Peptigrity does not sell, endorse, or recommend products or vendors.